Health and Healthcare
Health and Healthcare Articles
Kamada has announced initial interim results from its ongoing midstage coronavirus study of its treatment of COVID-19 patients with pneumonia.
Published:
Corbus Pharmaceuticals has reported that its systemic sclerosis study failed to reach the endpoints, and investors were not pleased.
Published:
On Thursday, Akebia Therapeutics Inc. (NASDAQ: AKBA) announced topline results from the Phase 3 PRO2TECT studies evaluating the safety and efficacy of vadadustat in chronic kidney disease (CKD)....
Published:
Auris Medical has reported topline data from its Phase 2 Travers trial with intranasal betahistine in vertigo.
Published:
America and the rest of the world is getting ready for a vaccine that will help protect public health against the COVID-19 pandemic. The societal impact of the coronavirus has changed many lives, and...
Published:
Jounce Therapeutics Inc. (NASDAQ: JNCE) made a massive gain on Tuesday after the company announced a licensing agreement with Gilead Sciences Inc. (NASDAQ: GILD). This deal is for the discovery and...
Published:
Plus Therapeutics shares rallied on Tuesday after an FDA update on its treatment of patients with recurrent glioblastoma.
Published:
Three U.S. COVID-19 vaccine trials are now in Phase 3 studies. All three appear to have some serious benefits, but none are approved yet.
Published:
The prize for Nestle in its acquisition of Aimmune Therapeutics is Palforzia, the world’s first treatment for a food allergy.
Published:
Health care services provider GoodRX has filed the SEC for its initial public offering.
Published:
Akcea Therapeutics stock jumped on Monday after it was announced that Ionis Pharmaceuticals would be acquiring all of its outstanding shares.
Published:
These five dividend-paying large-cap pharmaceutical stocks look like outstanding ideas for nervous investors looking for income and a degree of safety. They have come way in from their 52-week...
Published:
Fluidigm made a splash with the markets on Wednesday morning after the company announced a critical update from the FDA in regards to its COVID-19 test.
Published:
Independent research firm Argus has reiterated its Buy rating on Moderna and is calling this large pullback a buying opportunity.
Published:
The August 14 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Published:
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.